...: The study aimed to assess the safety, immunogenicity, and efficacy of long-term therapy with biosimilar of eculizumab (Elizaria ® ) in paroxysmal nocturnal hemoglobinuria (PNH) patients. Methods: The study included 30 patients with PNH who had completed previous clinical trials. Of these, 25 patients...

... and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) and inadequate response to eculizumab. Methods: This analysis evaluates the efficacy and safety of pegcetacoplan for Japanese patients in PEGASUS, as they are known for different clinicopathologic...

...), are appropriate next lines of therapy. In this study, the comparative safety, effectiveness, and cost of care between fostamatinib and the TPOs were evaluated in a real-world setting. Methods: A retrospective analysis of 17 community hematology practices across the USA was conducted to identify adult ITP patients...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2022 Elotuzumab Multiple myeloma Once weekly Efficacy Safety Multiple myeloma...

... progressive improvement. Our case suggests a strong association between COVID-19 vaccination and the exacerbation of ITP. COVID-19 mRNA vaccine Immune thrombocytopenia Safety Surveillance Platelet count A 65-year-old male patient known for immune thrombocytopenic purpura presented with three...

...Anat Gafter-Gvili; Ariadna Tibau; Pia Raanani; Daniel Shepshelovich The prevalence of safety-related postmarketing label modifications of medications for hematological malignancies is unknown. We identified 35 new drugs indicated for hematological malignancies approved by the US Food and Drug...

... of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher...

..., the efficacy and safety of rituximab treatment in the management of patients with resistant pITP. 27 03 2013 12 09 2013 19 12 2013 © 2013 S. Karger AG, Basel 2013 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated...